嵌合抗原受体 (CAR) 技术彻底改变了细胞免疫疗法，特别是 CAR-T 细胞在治疗血液恶性肿瘤方面取得了成功。然而，CAR-T细胞对抗实体瘤的功效有限。为了解决这些局限性，CAR-巨噬细胞 (CAR-Ms) 利用巨噬细胞的先天特性以及 CAR 技术的特异性和效力，为癌症免疫治疗提供了一种新颖且有前景的方法。临床前研究表明，即使在具有挑战性的微环境中，CAR-Ms也可以通过表现出直接细胞毒性并增强其他免疫细胞的招募和激活，有效地靶向和破坏肿瘤细胞。此外，与 CAR-T 细胞相比，巨噬细胞良好的安全性及其在实体瘤中的持久性使 CAR-M 成为潜在更安全、更持久的治疗选择。本综述探讨了 CAR-Ms 技术的最新进展，包括优化其抗肿瘤功效的工程策略以及支持其使用的临床前证据。我们还讨论了开发 CAR-Ms 疗法的挑战和未来方向，强调它们彻底改变细胞免疫疗法的潜力。通过利用巨噬细胞的独特特性，CAR-M 提供了一种突破性的方法来克服 CAR-T 细胞疗法当前的局限性，为更有效和可持续的癌症治疗铺平道路。版权所有 © 2024 Huang、Bei、Hu 和 Li。

Chimeric Antigen Receptor (CAR) technology has revolutionized cellular immunotherapy, particularly with the success of CAR-T cells in treating hematologic malignancies. However, CAR-T cells have the limited efficacy of against solid tumors. To address these limitations, CAR-macrophages (CAR-Ms) leverage the innate properties of macrophages with the specificity and potency of CAR technology, offering a novel and promising approach to cancer immunotherapy. Preclinical studies have shown that CAR-Ms can effectively target and destroy tumor cells, even within challenging microenvironments, by exhibiting direct cytotoxicity and enhancing the recruitment and activation of other immune cells. Additionally, the favorable safety profile of macrophages and their persistence within solid tumors position CAR-Ms as potentially safer and more durable therapeutic options compared to CAR-T cells. This review explores recent advancements in CAR-Ms technology, including engineering strategies to optimize their anti-tumor efficacy and preclinical evidence supporting their use. We also discuss the challenges and future directions in developing CAR-Ms therapies, emphasizing their potential to revolutionize cellular immunotherapy. By harnessing the unique properties of macrophages, CAR-Ms offer a groundbreaking approach to overcoming the current limitations of CAR-T cell therapies, paving the way for more effective and sustainable cancer treatments.Copyright © 2024 Huang, Bei, Hu and Li.